Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody. 2017

Tadanobu Nagaya, and Yuko Nakamura, and Kazuhide Sato, and Toshiko Harada, and Peter L Choyke, and James W Hodge, and Jeffrey Schlom, and Hisataka Kobayashi
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States of America.

Near Infrared-Photoimmunotherapy (NIR-PIT) is a highly selective tumor treatment that employs an antibody-photo-absorber conjugate (APC). Programmed cell death protein-1 ligand (PD-L1) is emerging as a molecular target. Here, we describe the efficacy of NIR-PIT, using fully human IgG1 anti-PD-L1 monoclonal antibody (mAb), avelumab, conjugated to the photo-absorber, IR700DX, in a PD-L1 expressing H441 cell line, papillary adenocarcinoma of lung. Avelumab-IR700 showed specific binding and cell-specific killing was observed after exposure of the cells to NIR in vitro. In the in vivo study, avelumab-IR700 showed high tumor accumulation and high tumor-background ratio. Tumor-bearing mice were separated into 4 groups: (1) no treatment; (2) 100 μg of avelumab-IR700 i.v.; (3) NIR light exposure only, NIR light was administered; (4) 100 μg of avelumab-IR700 i.v., NIR light was administered. Tumor growth was significantly inhibited by NIR-PIT treatment compared with the other groups (p < 0.001), and significantly prolonged survival was achieved (p < 0.01 vs other groups). In conclusion, the anti-PD-L1 antibody, avelumab, is suitable as an APC for NIR-PIT. Furthermore, NIR-PIT with avelumab-IR700 is a promising candidate of the treatment of PD-L1-expressing tumors that could be readily translated to humans.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007259 Infrared Rays That portion of the electromagnetic spectrum usually sensed as heat. Infrared wavelengths are longer than those of visible light, extending into the microwave frequencies. They are used therapeutically as heat, and also to warm food in restaurants. Heat Waves,Heat Wave,Infrared Ray,Ray, Infrared,Rays, Infrared,Wave, Heat,Waves, Heat
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D010789 Phototherapy Treatment of disease by exposure to light, especially by variously concentrated light rays or specific wavelengths. Blue Light Therapy,Blue-light Therapy,Light Therapy,Photoradiation Therapy,Red Light Phototherapy,Therapy, Photoradiation,Blue Light Therapies,Blue-light Therapies,Light Phototherapies, Red,Light Phototherapy, Red,Light Therapies,Light Therapies, Blue,Light Therapy, Blue,Photoradiation Therapies,Phototherapies,Phototherapies, Red Light,Phototherapy, Red Light,Red Light Phototherapies,Therapies, Blue Light,Therapies, Blue-light,Therapies, Light,Therapies, Photoradiation,Therapy, Blue Light,Therapy, Blue-light,Therapy, Light
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005456 Fluorescent Dyes Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. Flourescent Agent,Fluorescent Dye,Fluorescent Probe,Fluorescent Probes,Fluorochrome,Fluorochromes,Fluorogenic Substrates,Fluorescence Agents,Fluorescent Agents,Fluorogenic Substrate,Agents, Fluorescence,Agents, Fluorescent,Dyes, Fluorescent,Probes, Fluorescent,Substrates, Fluorogenic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000074322 Antineoplastic Agents, Immunological Antineoplastic agents containing immunological agents (e.g. MAbs). These pharmacologic preparations inhibit or prevent the proliferation of NEOPLASMS. Antineoplastic MAbs,Antineoplastics, Monoclonal Antibodies,Antineoplastics, Monoclonal Antibody,MAbs, Antineoplastic,Monoclonal Antibodies, Antineoplastic,Antibodies Antineoplastics, Monoclonal,Antineoplastic Monoclonal Antibodies,Immunological Antineoplastic Agents,Monoclonal Antibodies Antineoplastics,Monoclonal Antibody Antineoplastics

Related Publications

Tadanobu Nagaya, and Yuko Nakamura, and Kazuhide Sato, and Toshiko Harada, and Peter L Choyke, and James W Hodge, and Jeffrey Schlom, and Hisataka Kobayashi
October 2019, Journal for immunotherapy of cancer,
Tadanobu Nagaya, and Yuko Nakamura, and Kazuhide Sato, and Toshiko Harada, and Peter L Choyke, and James W Hodge, and Jeffrey Schlom, and Hisataka Kobayashi
January 2018, Oncoimmunology,
Tadanobu Nagaya, and Yuko Nakamura, and Kazuhide Sato, and Toshiko Harada, and Peter L Choyke, and James W Hodge, and Jeffrey Schlom, and Hisataka Kobayashi
January 2019, Human vaccines & immunotherapeutics,
Tadanobu Nagaya, and Yuko Nakamura, and Kazuhide Sato, and Toshiko Harada, and Peter L Choyke, and James W Hodge, and Jeffrey Schlom, and Hisataka Kobayashi
January 2019, Molecular imaging,
Tadanobu Nagaya, and Yuko Nakamura, and Kazuhide Sato, and Toshiko Harada, and Peter L Choyke, and James W Hodge, and Jeffrey Schlom, and Hisataka Kobayashi
February 2020, Journal for immunotherapy of cancer,
Tadanobu Nagaya, and Yuko Nakamura, and Kazuhide Sato, and Toshiko Harada, and Peter L Choyke, and James W Hodge, and Jeffrey Schlom, and Hisataka Kobayashi
January 2022, Cancers,
Tadanobu Nagaya, and Yuko Nakamura, and Kazuhide Sato, and Toshiko Harada, and Peter L Choyke, and James W Hodge, and Jeffrey Schlom, and Hisataka Kobayashi
June 2023, The Journal of veterinary medical science,
Tadanobu Nagaya, and Yuko Nakamura, and Kazuhide Sato, and Toshiko Harada, and Peter L Choyke, and James W Hodge, and Jeffrey Schlom, and Hisataka Kobayashi
September 2019, Journal of diabetes investigation,
Tadanobu Nagaya, and Yuko Nakamura, and Kazuhide Sato, and Toshiko Harada, and Peter L Choyke, and James W Hodge, and Jeffrey Schlom, and Hisataka Kobayashi
August 2019, Archives of gynecology and obstetrics,
Tadanobu Nagaya, and Yuko Nakamura, and Kazuhide Sato, and Toshiko Harada, and Peter L Choyke, and James W Hodge, and Jeffrey Schlom, and Hisataka Kobayashi
February 2022, Journal of nanobiotechnology,
Copied contents to your clipboard!